Status: Recruiting
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with p53 mutation.
Participants needed: 50
Trial details
Phase: Phase 2Age: Up to 18Biological sex: AllType: InterventionalSponsor: Yang LiUpdated: Jan 3, 2024Locations: 1
Eligibility criteria
Pathological diagnosis basis of malignant tumor； [+4]